iRegene Therapeutics
Cell Therapy Product Developer
2025Year10Month23Day,National Medical Products Administration (NMPA) officially approved iRegene (hereinafter referred to as“iRegene”) underNouvNeu004InjectionI-IIIApplication for the Entire Cycle Clinical Trial.This marks the world's first targeted therapy for Multiple System Atrophy (Multiple System Atrophy, MSA) cell therapy product officially enters the clinical stage.This timeNouvNeu004InjectionI-IIIThe approval of the full-cycle clinical trial for this“Incurable”Brings Breakthrough Hope to the Field of Neurodegenerative Diseases.
Rare Disease Treatment in a Predicament, MSA Patients in Urgent Need of Effective Therapies
Multiple System Atrophy (MSA) is a rapidly progressing adult neurodegenerative disease,MSAThe pathological core lies inα-Abnormal aggregation of synuclein in oligodendrocytes leads to myelin damage and nerve conduction disorders, which gradually destroys multiple key brain regions. This mechanism is fundamentally different from neurodegenerative diseases such as Parkinson's disease, which is why conventional neurological treatment strategies are not effective against it.MSAThe treatment often yields minimal results, with patients typically exhibiting a combination of autonomic dysfunction, Parkinsonism, and cerebellar ataxia. The condition is complex, posing significant challenges in diagnosis and treatment.MSADeveloping rapidly, most patients after diagnosis6To10Facing life-threatening conditions within the year, there is currently no specific therapy available on the market globally that can delay or halt the progression of the disease.
"Neurotrophic + Neural Reconstruction" New Treatment Strategy
This approvalNouvNeu004Injection is a chemically induced, functionally enhanced neural progenitor cell with the ability to secrete neurotrophic factors efficiently.NouvNeu004The injection solution adopts innovative“Neurotrophic+The composite treatment strategy of "nerve reconstruction" includes a combined mechanism of action: the injection provides nutritional support to endangered cells in the lesion area, preventing further cell death; meanwhile, it induces differentiation into nerve cells at multiple lesion sites through microenvironment modulation, achieving systematic nerve repair and functional reconstruction.
Top Team Joins Forces to Tackle Challenges, Patient Recruitment to Launch Soon
The clinical trial will be jointly conducted by the Rare Neurological Diseases Clinical and Translational Center at Beijing Tiantan Hospital. Professor Wang Yilong, a well-known expert in the field of neurology in China and the executive vice president of Beijing Tiantan Hospital, Capital Medical University, will serve as the principal investigator. This collaboration adheres to the patient-centered concept, aiming to accelerate the research and development and implementation process of new drugs, striving for multiple system atrophy (MSA) Brings New Hope for Treatment to Patients.
This collaboration is not only an advantageous integration of clinical resources and industrial strength, but also a deep fusion of medical humanistic care and scientific research innovation. In the trial drug "NouvNeu004"Upon approval to commence clinical research, all research centers have fully initiated preliminary preparations,It is expected to be released this year.12Recruitment starts nationwide in ChinaMSAPatient.
Global R&D Continues to Lead, Pipeline Layout Demonstrates Core Strength
Dr. Meng Cai, Chief Medical Officer of iRegene, stated,NouvNeu004The clinical approval not only solidified the company's R&D advantages in the field of neurodegenerative diseases, but alsoMSAPatients are provided with unprecedented treatment options.
iRegene's global competitiveness in the field of central nervous system diseases is accelerating. Its core product for Parkinson's diseaseNouvNeu001, the R&D progress has firmly ranked among the top tier of similar pipelines globally and has repeatedly gained international recognition:
Following2024Year3Month ObtainedFDAAfter special exemption, in the same year6Monthly AcquisitionFDAApproval to Initiate International Multicenter in the United States and Other CountriesIPhase clinical trial.
2025Year8Month15Day,NouvNeu001Furthermore, byFDAGranting Fast Track Designation (Fast Track Designation, FTD), becoming the first in the world to receive this designation.iPSCSource Universal Parkinson's Cell Therapy Product.
This series of milestone events, together with thisNouvNeu004The clinical approval jointly confirms that iRegene's "AI+The technical advantages centered on the "chemical induction" platform, along with its continuous innovative strength and global influence in the field of cell therapy.
